重组人脑利钠肽联合沙库巴曲缬沙坦治疗重症心衰的效果分析

Analysis of the Effect of Recombinant Human Brain Natriuretic Peptide Combined with Sacubitril Valsartan in the Treatment of Severe Heart Failure

目的分析重组人脑利钠肽与沙库巴曲缬沙坦联合运用于重症心衰患者中的治疗效果。方法随机选取2022年7月—2023年7月仁怀市中医院收治的60例重症心衰患者为研究对象,以随机数表法分为对照组(沙库巴曲缬沙坦治疗)、观察组(重组人脑利钠肽+沙库巴曲缬沙坦治疗),每组30例。比较两组治疗有效率、心功能及血清指标、不良反应发生率。结果观察组治疗总有效率为96.67%,高于对照组的70.00%,差异有统计学意义(χ^(2)=7.680,P<0.05)。治疗后,与对照组比较,观察组心率、左室舒张末期内径更低,左室射血分数更高,差异有统计学意义(P均<0.05)。治疗后,观察组超敏肌钙蛋白T、N末端脑钠肽原指标水平低于对照组,差异有统计学意义(P均<0.05)。观察组不良反应总发生率低于对照组,差异有统计学意义(P<0.05)。结论对重症心衰患者治疗期间,联合运用沙库巴曲缬沙坦和重组人脑利钠肽,能改善心功能,降低患者相关的血清指标水平,治疗安全性以及有效性有所保障。

Objective To analyze the therapeutic effect of recombinant human brain natriuretic peptide combined with sacubitril valsartan in patients with severe heart failure.Methods A total of 60 patients with severe heart failure admitted to Renhuai Hospital of Traditional Chinese Medicine from July 2022 to July 2023 were randomly selected as the study objects and divided into control group(treated with sackubactril and valsartan)and observation group(treated with recombinant human brain natriuretic peptide plus sackubactril and valsartan)by random number table method,with 30 cases in each group.The effective rate,cardiac function,serum indexes and the incidence of adverse reactions of the two groups were compared.Results The total effective rate of the observation group was 96.67%,which was higher than that of the control group(70.00%),and the difference was statistically significant(χ^(2)=7.680,P<0.05).After treatment,compared with control group,the heart rate and left ventricular end-diastolic diameter in observation group were lower,and left ventricular ejection fraction was higher,and the differences were statistically significant(all P<0.05).After treatment,the levels of cardiacmuscle troponin T and N terminal Pro B trpe natriuretic peptide in observation total group were lower than those in control group,and the differences were statistically significant(both P<0.05).The incidence of adverse reactions in observation group was lower than that in control group,and the difference was statistically significant(P<0.05).Conclusion During the treatment of patients with severe heart failure,the joint use of sacubitril valsartan and recombinant human brain natriuretic peptide will improve cardiac function,reduce the relevant serum indexes of the patients,and the therapeutic safety as well as the effectiveness of the treatment are guaranteed.